Merck & Co., Inc. to Appeal Reduced Jury Verdict in Federal FOSAMAX(R) (alendronate sodium) Case

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck’s request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

MORE ON THIS TOPIC